Ruvim Izikson

1.3k total citations
20 papers, 929 citations indexed

About

Ruvim Izikson is a scholar working on Epidemiology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Ruvim Izikson has authored 20 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Epidemiology, 5 papers in Infectious Diseases and 3 papers in Molecular Biology. Recurrent topics in Ruvim Izikson's work include Influenza Virus Research Studies (17 papers), Respiratory viral infections research (14 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Ruvim Izikson is often cited by papers focused on Influenza Virus Research Studies (17 papers), Respiratory viral infections research (14 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Ruvim Izikson collaborates with scholars based in United States, Austria and Canada. Ruvim Izikson's co-authors include Manon Cox, Lisa M. Dunkle, P. Patriarca, Karen L. Goldenthal, Derek Muse, Raffael Nachbagauer, Florian Krammer, Peter Palese, Penny Post and Janice D. Callahan and has published in prestigious journals such as New England Journal of Medicine, PEDIATRICS and CHEST Journal.

In The Last Decade

Ruvim Izikson

20 papers receiving 881 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruvim Izikson United States 12 769 240 239 219 98 20 929
Angela Choi United States 14 711 0.9× 304 1.3× 409 1.7× 174 0.8× 132 1.3× 23 1.0k
Vamsee Mallajosyula United States 11 391 0.5× 262 1.1× 221 0.9× 167 0.8× 92 0.9× 23 663
Diane Niño United States 13 915 1.2× 288 1.2× 481 2.0× 252 1.2× 83 0.8× 14 1.1k
Mark A. Yondola United States 11 710 0.9× 214 0.9× 368 1.5× 173 0.8× 88 0.9× 15 855
Giulia Lapini Italy 12 302 0.4× 238 1.0× 132 0.6× 143 0.7× 35 0.4× 19 574
Irina Isakova–Sivak Russia 20 834 1.1× 388 1.6× 342 1.4× 165 0.8× 57 0.6× 76 998
Andrea L. Cathcart United States 13 468 0.6× 409 1.7× 115 0.5× 219 1.0× 33 0.3× 24 944
Cecilia Chui United Kingdom 5 584 0.8× 246 1.0× 535 2.2× 136 0.6× 26 0.3× 6 925
William M. Hurni United States 13 392 0.5× 184 0.8× 238 1.0× 212 1.0× 123 1.3× 25 804
Teddy John Wohlbold United States 14 1.0k 1.4× 272 1.1× 433 1.8× 192 0.9× 213 2.2× 19 1.2k

Countries citing papers authored by Ruvim Izikson

Since Specialization
Citations

This map shows the geographic impact of Ruvim Izikson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruvim Izikson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruvim Izikson more than expected).

Fields of papers citing papers by Ruvim Izikson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruvim Izikson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruvim Izikson. The network helps show where Ruvim Izikson may publish in the future.

Co-authorship network of co-authors of Ruvim Izikson

This figure shows the co-authorship network connecting the top 25 collaborators of Ruvim Izikson. A scholar is included among the top collaborators of Ruvim Izikson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruvim Izikson. Ruvim Izikson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hsiao, Amber, John Hansen, Bruce Fireman, et al.. (2025). Effectiveness of Nirsevimab Against RSV and RSV-Related Events in Infants. PEDIATRICS. 156(2). 3 indexed citations
2.
Hsiao, Amber, Ruvim Izikson, Bruce Fireman, et al.. (2024). Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infants. AJOG Global Reports. 4(4). 100395–100395. 2 indexed citations
3.
Hansen, John, Julius Timbol, Bruce Fireman, et al.. (2024). Effectiveness of nirsevimab in infants against respiratory syncytial virus and related events. Annals of Allergy Asthma & Immunology. 133(6). S3–S4. 1 indexed citations
4.
Hsiao, Amber, John Hansen, Ned Lewis, et al.. (2022). Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study. Vaccine. 40(5). 774–779. 2 indexed citations
5.
Hansen, John, Kristin Goddard, Julius Timbol, et al.. (2020). Safety of Recombinant Influenza Vaccine Compared to Inactivated Influenza Vaccine in Adults: An Observational Study. Open Forum Infectious Diseases. 7(6). ofaa179–ofaa179. 4 indexed citations
6.
Dunkle, Lisa M., Ruvim Izikson, P. Patriarca, et al.. (2018). Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial. PEDIATRICS. 141(5). 13 indexed citations
7.
Rajendran, Madhusudan, Raffael Nachbagauer, Megan E. Ermler, et al.. (2017). Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin. mBio. 8(2). 113 indexed citations
8.
Stadlbauer, Daniel, Arvind Rajabhathor, Fatima Amanat, et al.. (2017). Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans. mSphere. 2(6). 34 indexed citations
9.
Dunkle, Lisa M., Ruvim Izikson, P. Patriarca, et al.. (2017). Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older. New England Journal of Medicine. 376(25). 2427–2436. 180 indexed citations
10.
Dunkle, Lisa M., Ruvim Izikson, P. Patriarca, et al.. (2017). Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18–49 Years of Age. The Journal of Infectious Diseases. 216(10). 1219–1226. 37 indexed citations
11.
Treanor, John J., Laurence Chu, Brandon Essink, et al.. (2017). Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial. Vaccine. 35(6). 923–928. 9 indexed citations
12.
Nachbagauer, Raffael, Angela Choi, Ruvim Izikson, et al.. (2016). Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. mBio. 7(1). e01996–15. 105 indexed citations
13.
Dunkle, Lisa M. & Ruvim Izikson. (2016). Recombinant hemagglutinin influenza vaccine provides broader spectrum protection. Expert Review of Vaccines. 15(8). 957–966. 22 indexed citations
14.
Izikson, Ruvim, David J. Leffell, S. Allan Bock, et al.. (2015). Randomized comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age. Vaccine. 33(48). 6622–6628. 20 indexed citations
15.
Cox, Manon, Ruvim Izikson, Penny Post, & Lisa M. Dunkle. (2015). Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. PubMed. 3(4). 97–108. 98 indexed citations
16.
17.
Izikson, Ruvim, et al.. (2013). Safety and Immunogenicity of Flublok®, a Highly Purified Recombinant Recombinant Influenza Vaccine Made without Eggs or Live Influenza Viruses. Journal of Allergy and Clinical Immunology. 131(2). AB11–AB11. 1 indexed citations
18.
Treanor, John J., Hana M. El Sahly, James C. King, et al.. (2011). Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial. Vaccine. 29(44). 7733–7739. 129 indexed citations
19.
20.
Izikson, Ruvim, et al.. (2008). SPIROMETRIC FEATURES OF PATIENTS WITH EXCESSIVE DYNAMIC EXPIRATORY CENTRAL AIRWAY COLLAPSE. CHEST Journal. 134(4). 28S–28S. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angela Choi Breakdown of academic impact, for papers by Vamsee Mallajosyula Breakdown of academic impact, for papers by Diane Niño Breakdown of academic impact, for papers by Mark A. Yondola Breakdown of academic impact, for papers by Giulia Lapini Breakdown of academic impact, for papers by Irina Isakova–Sivak Breakdown of academic impact, for papers by Andrea L. Cathcart Breakdown of academic impact, for papers by Cecilia Chui Breakdown of academic impact, for papers by William M. Hurni Breakdown of academic impact, for papers by Teddy John Wohlbold
Rankless by CCL
2026